<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathogenesis of Hodgkin lymphoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathogenesis of Hodgkin lymphoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathogenesis of Hodgkin lymphoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jon C Aster, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Olga Pozdnyakova, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard F Ambinder, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hodgkin lymphoma (HL) refers to lymphoid neoplasms in which distinctive malignant lymphoid cells are admixed with a much larger population of non-neoplastic inflammatory cells and/or fibrosis. There are two broad categories of HL that differ in important ways, including the morphology and immunophenotype of the malignant cells, clinical presentation, prognosis, and management:</p><p class="bulletIndent1"><span class="glyph">●</span>Classic HL (cHL)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nodular lymphocyte-predominant HL (NLPHL) </p><p></p><p>Notably, in one of the two current classifications of hematologic malignancies, the International Consensus Classification (ICC) [<a href="#rid1">1</a>], NLPHL has been renamed nodular lymphocyte predominant B cell lymphoma, while the name NLPHL is retained in the 5<sup>th</sup> edition of the World Health Organization Classification of Hematologic Malignancies [<a href="#rid2">2</a>].</p><p>This topic discusses the pathogenesis of cHL.</p><p>The pathogenesis of NLPHL is discussed separately. (See  <a class="medical medical_review" href="/d/html/4730.html" rel="external">"Nodular lymphocyte-predominant Hodgkin lymphoma: Clinical manifestations, diagnosis, and staging", section on 'Pathogenesis'</a>.)</p><p>Clinical presentation and diagnosis of cHL and NLPHL are discussed separately. (See  <a class="medical medical_review" href="/d/html/4688.html" rel="external">"Clinical presentation and diagnosis of classic Hodgkin lymphoma in adults"</a> and  <a class="medical medical_review" href="/d/html/4730.html" rel="external">"Nodular lymphocyte-predominant Hodgkin lymphoma: Clinical manifestations, diagnosis, and staging"</a>.)</p><p class="headingAnchor" id="H2605141009"><span class="h1">OVERVIEW OF HODGKIN LYMPHOMA</span><span class="headingEndMark"> — </span>HL, formerly called Hodgkin's disease, is a hematologic malignancy in which characteristic, large, dysplastic mononuclear and multinucleated cells are surrounded by variable mixtures of mature, non-neoplastic, inflammatory cells and fibrosis [<a href="#rid2">2,3</a>].</p><p>There are two major categories of HL according to current classification systems, the International Consensus Classification (ICC) [<a href="#rid1">1</a>] and the 5<sup>th</sup> edition of the World Health Organization Classification of Hematologic Malignancies (WHO5) [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Classic HL (cHL) accounts for approximately 90 to 95 percent of cases of HL</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nodular lymphocyte-predominant HL (NLPHL; called nodular lymphocyte predominant B cell lymphoma in the ICC) accounts for the remainder </p><p></p><p>These two broad categories of cHL and NLPHL differ in clinical presentation, demographic features, and pathology and are discussed separately. (See  <a class="medical medical_review" href="/d/html/4691.html" rel="external">"Hodgkin lymphoma: Epidemiology and risk factors"</a> and  <a class="medical medical_review" href="/d/html/4688.html" rel="external">"Clinical presentation and diagnosis of classic Hodgkin lymphoma in adults"</a> and  <a class="medical medical_review" href="/d/html/4730.html" rel="external">"Nodular lymphocyte-predominant Hodgkin lymphoma: Clinical manifestations, diagnosis, and staging"</a>.)</p><p class="headingAnchor" id="H3985256842"><span class="h1">CLASSIC HODGKIN LYMPHOMA</span><span class="headingEndMark"> — </span>Classic HL (cHL) typically presents with painless peripheral adenopathy in one or two lymph node-bearing areas and may be associated with mediastinal adenopathy, splenic or other abdominal involvement, and/or constitutional symptoms of fever, drenching sweats, or weight loss. There are four categories of cHL:</p><p class="bulletIndent1"><span class="glyph">●</span>Nodular sclerosis (NS cHL)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lymphocyte-rich (LR cHL)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mixed cellularity (MC cHL) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lymphocyte-depleted (LD cHL)</p><p></p><p>Demographic features, clinical presentation, and prognosis of these categories are discussed separately. (See  <a class="medical medical_review" href="/d/html/4691.html" rel="external">"Hodgkin lymphoma: Epidemiology and risk factors"</a> and  <a class="medical medical_review" href="/d/html/4688.html" rel="external">"Clinical presentation and diagnosis of classic Hodgkin lymphoma in adults"</a>.)</p><p class="headingAnchor" id="H1632745701"><span class="h2">Histology of cHL</span><span class="headingEndMark"> — </span>In cHL, the lymph node architecture is effaced by an infiltrate of malignant cells admixed with a large and heterogeneous population of nonmalignant inflammatory cells and a variable degree of fibrosis (<a class="graphic graphic_picture graphicRef54520" href="/d/graphic/54520.html" rel="external">picture 1</a>). (See  <a class="medical medical_review" href="/d/html/4688.html" rel="external">"Clinical presentation and diagnosis of classic Hodgkin lymphoma in adults", section on 'Pathology'</a>.)</p><p class="headingAnchor" id="H37404453"><span class="h2">Cellular components of cHL</span></p><p class="headingAnchor" id="H2161103907"><span class="h3">Hodgkin/Reed-Sternberg cells</span><span class="headingEndMark"> — </span>The malignant cells of cHL are called Hodgkin/Reed-Sternberg (HRS) cells and they account for only a small fraction of the cellular infiltrate (estimated to be 0.1 to 10 percent) [<a href="#rid3">3</a>]. </p><p class="headingAnchor" id="H1152259504"><span class="h4">Microscopy of cHL</span><span class="headingEndMark"> — </span>The characteristic microscopic appearance of HRS cells is a distinctive binucleate morphology with large inclusion-like nucleoli (<a class="graphic graphic_picture graphicRef69090" href="/d/graphic/69090.html" rel="external">picture 2</a>) that resembles owl's eyes; variants of HRS cells in cHL may be mononuclear or multi-nuclear. The bi- or multi-nucleate morphology of HRS cells results from incomplete cytokinesis of mononuclear Hodgkin cells [<a href="#rid4">4,5</a>]. </p><p class="headingAnchor" id="H3283442052"><span class="h4">Immunophenotype</span><span class="headingEndMark"> — </span>Their characteristic immunophenotype (expression of CD30 and CD15, but not CD20) distinguishes HRS cells from normal B lymphocytes and from other types of lymphoma.</p><p>HRS cells typically express CD30 and CD15, and lack CD45 [<a href="#rid3">3</a>]. This immunophenotype is distinctive because CD45 (also known as leukocyte common antigen) is expressed by almost all other types of lymphoid cells; CD15 is usually expressed on granulocytes and monocytes, but not on resting B cells; and expression of CD30 is commonly seen only on HRS cells, anaplastic large cell lymphoma, and embryonal carcinoma [<a href="#rid6">6</a>]. Expression of CD30 enables CD30-directed immunotherapy in cHL. (See  <a class="medical medical_review" href="/d/html/4765.html" rel="external">"Treatment of relapsed or refractory classic Hodgkin lymphoma"</a>.)</p><p>HRS cells usually express low levels of PAX5 (also known as BSAP), a transcription factor restricted to B cells, whereas expression of CD20 (a marker on most B cells) and BCL6 (a characteristic marker of germinal center [GC] B cells) is seen on HRS cells in only a minority of cases [<a href="#rid7">7</a>]. Immunohistochemical stains for most other B cell markers and T cell antigens are usually negative.</p><p>Additional details of the immunophenotype of HRS cells in cHL are provided separately. (See  <a class="medical medical_review" href="/d/html/4688.html" rel="external">"Clinical presentation and diagnosis of classic Hodgkin lymphoma in adults", section on 'Immunophenotype'</a> and  <a class="medical medical_review" href="/d/html/4730.html" rel="external">"Nodular lymphocyte-predominant Hodgkin lymphoma: Clinical manifestations, diagnosis, and staging", section on 'Immunophenotype'</a>.) </p><p class="headingAnchor" id="H1961919912"><span class="h4">Protein and gene expression</span><span class="headingEndMark"> — </span>Characteristic patterns of protein and gene expression distinguish HRS cells from normal B lymphocytes and other malignancies.</p><p>Despite their derivation from GC B lymphocytes, HRS cells have lost or down-regulated expression of characteristic B cell-specific genes [<a href="#rid8">8-10</a>]. As an example, decreased levels of immunoglobulin (Ig) mRNA and/or frameshift mutations in <em>IGH</em> prevent expression of Ig proteins in many cases of HL [<a href="#rid11">11,12</a>]. Epigenetic silencing of gene promoters also contributes to dysregulated gene expression [<a href="#rid13">13-16</a>]. </p><p>Transcription factors are implicated in aberrant gene expression by the HRS cells:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>AP1 (Activator protein 1)</strong> – The dimeric transcription factor, AP-1, is composed of proteins from the Jun (eg, c-Jun, JunB, JunD) and Fos (eg, c-Fos, FosB, Fra1, Fra2) families. HRS cells typically express high levels of c-Jun and JunB, and AP-1 is constitutively activated [<a href="#rid17">17</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Regulators of Ig expression</strong> – Transcription factors that are required for expression of <em>Ig,</em> including PU.1, Oct-2, and BOB1, are usually decreased or undetectable in HRS cells [<a href="#rid18">18-21</a>]. Although PAX5 is usually present, its low level of expression and/or codependence on transcription factors that are lost in HRS cells impair target gene expression. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>BCL6</strong> – In most cases, the HRS cells of cHL fail to express BCL6, a transcriptional repressor that is characteristic of normal GC B lymphocytes [<a href="#rid7">7</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Others</strong>: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High levels of activated B cell factor 1 antagonize the function of E2A and PAX5 and may contribute to loss of expression of B cell-specific genes [<a href="#rid22">22,23</a>]. Excessive activation of STAT5A and STAT5B have also been implicated in the downregulation of B cell-specific genes [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypoxia-induced upregulation of Id2 and NOTCH1 leads to increased JUN expression and enhanced nuclear factor kappa B (NF-kB) activity, both of which are characteristic of HRS cells [<a href="#rid25">25</a>]. Transient hypoxic conditions in the GC may thereby initiate an epigenetic switch towards an HRS cell-like phenotype and promote survival.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Downregulation of EBF1 may contribute to the loss of B cell phenotype, based on a report that enforced expression of EBF1 in cHL cell lines can upregulate several B cell markers (eg, CD19, CD79A, CD79B) [<a href="#rid26">26</a>].</p><p></p><p>Gene expression profiling has identified two major subgroups of HL that differentially express <em>MYC, IRF4, </em>and<em> NOTCH1</em>, but these patterns are not associated with particular histologic subtypes of cHL or Epstein-Barr virus (EBV) status [<a href="#rid27">27</a>]. </p><p class="headingAnchor" id="H381838229"><span class="h4">Cytogenetics and mutations</span><span class="headingEndMark"> — </span>HRS cells are frequently aneuploid and chromosomal abnormalities and gene mutations contribute to the development of HL [<a href="#rid10">10,28,29</a>]. Gain or loss of specific chromosomal regions and mutations of important regulatory genes promote altered growth and differentiation, enhanced survival, and may be responsible for the atypical nuclear morphology of HRS cells. The basis for genomic instability in HRS cells is uncertain.<strong> </strong></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common cytogenetic abnormalities</strong>: The most common cytogenetic findings in cHL are: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gain of chromosomes 2p, 9p, 16p, and 17q </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Loss of 13q, 6q, and 11q </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common gene mutations</strong>: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Genomic gains of <em>REL</em>, <em>JAK2</em>, <em>STAT6</em>, <em>NOTCH1</em>, and <em>JUNB</em> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inactivating mutations in <em>NFKB1A, NFKB1E, TNFAIP3, PIM1, Rho/TTF, SOCS1, IKBKB</em>, <em>CD40</em>, <em>BTK, CARD11, BCL10</em>, <em>MAP3K14, MYC, </em>and<em> PAX5</em> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mutations in the tumor suppressor genes, <em>CD95</em> and <em>TP53 </em></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mutations of major histocompatibility complex (MHC)-associated genes, such as <em>CIITA</em> and beta-2 microglobulin (<em>B2M</em>) (see <a class="local">'Loss of MHC molecule expression'</a> below)</p><p></p><p>Gene amplification of chromosome 9p24.1 is one of the most common abnormalities in cHL [<a href="#rid30">30</a>]. Chromosomal gains in this region deregulate at least four genes (<em>JAK2, JMJD2C, PDL1</em>, and <em>PDL2</em>) that contribute to the pathogenesis of HL. <em>JMJD2C</em> encodes a histone demethylase whose downregulation in HL cell lines induces cell death [<a href="#rid16">16</a>]. </p><p>Contributions of cytogenetic and molecular abnormalities to the pathogenesis of cHL are described below. (See <a class="local">'Aberrant signaling'</a> below and <a class="local">'Immune evasion'</a> below.)</p><p class="headingAnchor" id="H3184912390"><span class="h4">Cellular origin of HRS cells</span><span class="headingEndMark"> — </span>HRS cells are derived from germinal center (GC) B lymphocytes that have transformed during maturation, losing the capacity to express immunoglobulins and transcription factors that define normal B cells. HRS do not correspond to any identified stage of normal B cell development. (See  <a class="medical medical_review" href="/d/html/13933.html" rel="external">"Normal B and T lymphocyte development", section on 'B cell development'</a>.)</p><p>The recognition that HRS cells are derived from GC or post-GC B cells is based on their molecular features. Rearrangement of <em>Ig</em> genes in lymph node GCs and subsequent somatic hypermutation of Ig genes in follicles of secondary lymphoid organs are the most distinctive molecular events in mature B lymphoid cells [<a href="#rid31">31,32</a>]. Detection in microdissected single HRS cells of clonal rearrangements of the Ig heavy chain (<em>IGH</em>) and the high load of somatic mutations demonstrates they originate from GC/post-GC B lymphocytes [<a href="#rid9">9,11,31,33-36</a>]. </p><p>Rare patients have coexistent cHL and a non-Hodgkin lymphoma (NHL) in whom the HRS and NHL cells share identical <em>IGH</em> <em>VDJ</em> rearrangements and somatic mutations [<a href="#rid37">37-39</a>]. Thus, the initial transforming event occurred in a GC B lymphocyte that was the precursor of both the NHL and HRS cells, followed by acquisition of distinct secondary molecular lesions that accounted for the divergent phenotypes of the two diseases. Rarely, HRS cells have clonal rearrangements of T cell receptor genes, however, even in such cases the tumor cells generally also have clonal Ig rearrangements, indicating that such cases are also derived from GC B lymphocytes [<a href="#rid40">40</a>]. </p><p class="headingAnchor" id="H1110546476"><span class="h3">Nonmalignant infiltrate</span><span class="headingEndMark"> — </span>The cellular infiltrate in cHL consists of a heterogeneous mixture of nonmalignant inflammatory cells, which includes lymphocytes, macrophages, eosinophils, neutrophils, plasma cells, and mast cells. The inflammatory cells are attracted by signals from the malignant HRS cells. In turn, the inflammatory cells support the growth of the malignant cells and induce variable stromal reactions (eg, activation of fibroblasts and collagen deposition). The host immune cells fail to eliminate the malignant cells due to immunosuppressive factors expressed by HRS cells and the presence of immunosuppressive host cells, particularly infiltrating macrophages. (See <a class="local">'Immune evasion'</a> below.) </p><p class="headingAnchor" id="H1026375533"><span class="h1">PATHOGENESIS OF cHL</span><span class="headingEndMark"> — </span>The pathogenesis of classic HL (cHL) involves acquired mutations in oncogenes and tumor suppressor genes, aberrant autocrine and paracrine signaling, and escape from immune destruction:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mutations</strong> - Acquired mutations in oncogenes and tumor suppressor genes lead to enhanced signaling and aberrant activation of the transcription factor NF-kB. (See <a class="local">'Cytogenetics and mutations'</a> above and <a class="local">'Cellular origin of HRS cells'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autocrine/paracrine signaling</strong> – Aberrant autocrine and paracrine signaling by Hodgkin/Reed-Sternberg (HRS) cells that attracts inflammatory cells, which in turn support the proliferation and survival of HRS cells. (See <a class="local">'Aberrant signaling'</a> below and <a class="local">'Apoptosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Amplification of genes on chromosome 9</strong> – Gene amplifications associated with chromosome 9p24.1 led to deregulation of at least four genes (<em>JAK2, JMJD2C, PDL1</em>, and <em>PDL2</em>) that are important in the pathogenesis of HL. (See <a class="local">'Cytogenetics and mutations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protection from immune destruction</strong> – Protection of the malignant cells from immune destruction. (See <a class="local">'Immune evasion'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epstein-Barr virus (EBV)</strong> – EBV present in a subset of cHL cells and may contribute to HL pathogenesis by augmenting growth and/or inhibiting apoptosis. (See <a class="local">'Epstein-Barr virus'</a> below.)</p><p></p><p class="headingAnchor" id="H2438941261"><span class="h2">Aberrant signaling</span><span class="headingEndMark"> — </span>Mutations and disordered expression affect key signaling pathways in HRS cells, including nuclear factor kappa B (NF-kB), JAK/STAT, activator protein 1 (AP-1), tumor necrosis factor (TNF), and NOTCH1. These abnormalities, together with the robust inflammatory lymph node milieu and expression of cytokines and chemokines by HRS cells, contribute to the pathophysiology of cHL.</p><p class="headingAnchor" id="H2282448298"><span class="h3">NF-kB</span><span class="headingEndMark"> — </span>NF-kB refers to a family of multimeric transcription factors that play important roles in normal B cell function and neoplasia. NF-kB is constitutively activated in cHL, which promotes proliferation, reduces apoptosis, and induces expression of cytokines that recruit the immune cells that surround HRS cells.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>NF-kB function in normal lymphoid cells</strong> – NF-kB is a key regulator of the immune response to infections, stress, and cytokines. NF-kB is composed of homodimers and heterodimers that translocate from the cytoplasm to the nucleus in response to signals [<a href="#rid41">41</a>]. Most resting B cells do not have NF-kB in the nucleus because I-kappa-B (IkB) or other inhibitory proteins sequester NF-kB in the cytoplasm. </p><p></p><p class="bulletIndent1">Cellular stimuli lead to phosphorylation, ubiquitination, and degradation of IkB, which permits NF-kB factors to translocate to the nucleus and activate transcription of target genes. Normal mature B cells and HRS cells have two major types of NF-kB heterodimers: NF-kB1/c-REL and NF-kB1/REL-A [<a href="#rid42">42,43</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>NF-kB activation in HRS cells</strong> – Activation of NF-kB in HRS cells is mediated by [<a href="#rid30">30,44-53</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inactivating point mutations or deletions of negative regulators (eg, <em>IKB</em>, <em>TNFAIP3, NFKBIA, NFKBIE, TRAF3, CYLD</em>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Amplification by copy number gains of positive regulators or various components of the NF-kB pathway (eg, <em>NIK, REL, MAP3K14</em>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Expression of NF-kB target genes</strong> – Many NF-kB target genes are highly expressed in HRS cells. As an example, NF-kB activates expression of <em>IKBA</em>, which sequesters NF-kB and reduces signaling in normal B cells. However, mutations of <em>IKBA </em>in cHL may interrupt this negative feedback loop [<a href="#rid45">45,54,55</a>]. Other NF-kB target genes expressed in HRS cells include intercellular adhesion molecule (ICAM-1), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-6, and TNF, which contribute to recruitment and/or activation of non-neoplastic leukocytes that form the characteristic background of cHL [<a href="#rid56">56</a>]. (See  <a class="medical medical_review" href="/d/html/4691.html" rel="external">"Hodgkin lymphoma: Epidemiology and risk factors"</a>.)</p><p></p><p class="headingAnchor" id="H1211769727"><span class="h3">JAK-STAT</span><span class="headingEndMark"> — </span>Altered JAK-STAT signaling affects differentiation, proliferation, and survival of B lymphocytes and contributes to the development of cHL.</p><p>Janus kinase (JAK) proteins are tyrosine kinases that activate the signal transducer and activator of transcription (STAT) pathway. Most cases of cHL have mutations that are predicted to increase JAK-STAT signaling. Copy number gains of <em>JAK2</em> are seen in 20 percent of HL, inactivating mutations of the main negative regulators of the STAT pathway (ie, suppressor of cytokine signaling 1 [<em>SOCS1</em>] and protein tyrosine phosphatase N1 [<em>PTPN1</em>]) are common, and a variety of other aberrations involving JAK-STAT signaling pathway components have been described [<a href="#rid30">30,57-63</a>].</p><p class="headingAnchor" id="H3426672462"><span class="h3">NOTCH</span><span class="headingEndMark"> — </span>The NOTCH signaling pathway regulates normal T cell development and has been implicated in controlling some aspects of B cell maturation. The HRS cells of cHL express NOTCH1, they are surrounded by lymphocytes that express the NOTCH ligand JAGGED1, and HRS cell lines derived from cHL grow at an increased rate when exposed to NOTCH ligands [<a href="#rid64">64,65</a>]. NOTCH1 signals may contribute to aberrant differentiation of HRS cells because NOTCH1 activates T cell programs of gene expression at the expense of B cell programs [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H2990733132"><span class="h2">Cytokines/chemokines</span><span class="headingEndMark"> — </span>HRS cells express cytokines, chemokines, and other factors that act via autocrine and paracrine mechanisms. Together with mutations in signaling pathways, these factors contribute to HRS cell growth and survival. </p><p class="bulletIndent1"><span class="glyph">●</span>IL-13 – HRS cells frequently express both IL-13 and its receptor and establish an autocrine signaling loop may contribute to HL tumorigenesis [<a href="#rid67">67-69</a>]. The receptors for both IL-13 and IL-4 have two signaling chains in common and may activate overlapping downstream targets [<a href="#rid70">70</a>]. In normal B cells, IL-13 inhibits NF-kB activity by activating <em>IKBA</em> transcription, but <em>IKBA </em>mutations and/or constitutive degradation of IkB in HRS cells may interrupt this negative regulatory pathway and contribute to unbridled NF-kB activation [<a href="#rid45">45-47,71-73</a>]. IL-13 and IL-4 also activate JAK kinases and stimulate STAT6, a transcription factor that can interact with NF-kB to synergistically activate some target genes [<a href="#rid59">59,74-77</a>]. Expression <em>of E4BP4/NF-IL3</em>, which encodes a transcription factor that prevents apoptosis, may be due to autocrine signaling by IL-13 and IL-4 [<a href="#rid67">67,78-80</a>]. (See <a class="local">'Aberrant signaling'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TNF (Tumor necrosis factor)</strong> – HRS cells express TNF receptor proteins, including CD30, CD40, CD95, transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), B cell maturation antigen (BCMA), and receptor activator of NF-kB (RANK) [<a href="#rid81">81</a>]. Engagement of these receptors by their ligands activates signaling pathways that augment NF-kB activity [<a href="#rid62">62</a>]. In addition, as described below, EBV expresses latent membrane protein (LMP1), which is a constitutively active member of the TNF receptor (TNFR) superfamily. (See <a class="local">'Epstein-Barr virus'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interferon regulatory factors</strong> – HRS cells express abundant interferon regulatory factor 5 (IRF5), which plays a central role in Toll-like receptor (TLR)-mediated immune responses [<a href="#rid82">82</a>]. Constitutive activity of IRF5 may protect HRS cells from cell death and, in combination with NF-kB, IRF5 may contribute to expression of proinflammatory genes, downregulation of genes required for B cell differentiation, and upregulation of their transcriptional antagonists [<a href="#rid83">83</a>]. IRF5 mediates transcriptional activation of AP-1 (which increases CD30 expression) and upregulation of <em>JUN, JUNB, </em>and<em> ATF3</em> (which may modify NF-kB activity in HRS cells) [<a href="#rid17">17,84,85</a>].</p><p></p><p>Inflammatory cytokines released from the HRS cells of cHL may also contribute to fever, leukocytosis, anemia of chronic inflammation, elevation of the erythrocyte sedimentation rate, and immune abnormalities (eg, hypergammaglobulinemia, anergy) of HL [<a href="#rid86">86</a>]. (See  <a class="medical medical_review" href="/d/html/4688.html" rel="external">"Clinical presentation and diagnosis of classic Hodgkin lymphoma in adults", section on 'Clinical presentation'</a>.)</p><p class="headingAnchor" id="H3749060467"><span class="h2">Apoptosis</span><span class="headingEndMark"> — </span>Abnormal regulation of apoptosis enhances survival of HRS cells.</p><p>In normal B lymphocytes, the presence of nonfunctional immunoglobulin (Ig) genes leads to loss of anti-apoptosis signals. In cHL, HRS cells survive despite the presence of nonfunctional Ig genes, in part due to excessive NF-kB activation. Nonfunctional Ig genes occur most often in EBV-positive cHL, and EBV-associated activation of NF-kB may rescue HRS cells from apoptosis, as described below. (See <a class="local">'Epstein-Barr virus'</a> below.)</p><p>HRS cells of cHL often demonstrate abnormalities of p53, but they only rarely have mutations in <em>TP53</em>, which encodes p53. Amplification of <em>MDM2</em>, which encodes a protein that promotes p53 degradation, may cause p53 loss-of-function in some cases [<a href="#rid87">87</a>].</p><p class="headingAnchor" id="H20899515"><span class="h2">Immune evasion</span></p><p class="headingAnchor" id="H188728851"><span class="h3">Immune milieu</span><span class="headingEndMark"> — </span>Despite the abundance of immune cells in the cHL microenvironment that are attracted by signals from HRS cells, the malignant cells have developed mechanisms to survive by escaping immune surveillance. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune effector and regulator cells</strong> – HRS cells recruit CD4-positive T cells, macrophages, mast cells, and neutrophils by expression of CCL5, CCL17, CCL22, IL-8, lymphotoxin-alpha, and other cytokines and chemokines [<a href="#rid69">69,88-90</a>]. CCL17 and CCL22 also attract immunosuppressive T regulatory cells, while production of the immunosuppressive cytokine, IL-10, inhibits the function of infiltrating natural killer cells and cytotoxic T cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eosinophils</strong> – The HRS cells recruit eosinophils by expressing IL-5, CCL28, and TNF (which induces tissue fibroblasts to make eotaxin [CCL11]), and other chemoattractants [<a href="#rid91">91-93</a>]. IL-5 also increases marrow production of eosinophils through growth and survival effects on eosinophilic precursors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fibrosis</strong> – Tissue fibrosis, which is most characteristic of nodular sclerosis cHL, has been linked to HRS production of transforming growth factor (TGF) beta and basic fibroblast growth factor [<a href="#rid94">94,95</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Plasma cells</strong> – HRS cells elaborate CCL28, which together with galectin-1, IL-13, MDC, and TARC, promote accumulation and growth of T helper type 2 (TH2) cells. TH2 cells, in turn, augment plasma cell development.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Granuloma formation </strong>– Granuloma formation can be seen in tissues involved by cHL and occasionally at distant sites (eg, spleen and liver), even in the absence of direct cHL involvement. Distant granulomata were reported in approximately 15 percent of cHL cases, based on pathologic evaluation of staging splenectomies, liver biopsies, and autopsy studies [<a href="#rid96">96-99</a>]. Granulomata may persist following treatment in the absence of residual disease and are not thought to be clinically significant.</p><p></p><p class="headingAnchor" id="H1302041224"><span class="h3">Normal T cell activation</span><span class="headingEndMark"> — </span>Despite abundant T cells in the cHL tumor milieu, HRS cells are not eliminated because they exist in an immunoprotected niche that prevents T cell activation.</p><p>Activation of T cells requires two signals:</p><p class="bulletIndent1"><span class="glyph">●</span>Interaction of the T cell receptor (TCR) with a major histocompatibility complex (MHC)-bound antigen presented on the surface of an antigen presenting cell (APC).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A costimulatory signal from binding of B7-1 (CD80) or B7-2 (CD86) on the APC to CD28 on the surface of the T cell.</p><p></p><p>The strength and duration of T cell activation is modulated by co-inhibitory receptors, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1). Further details of T cell activation are presented separately. (See  <a class="medical medical_review" href="/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines", section on 'T cell activation and functions'</a>.) </p><p>Mechanisms by which T cells fail to eliminate HRS cells in HL are described below.</p><p class="headingAnchor" id="H3070761949"><span class="h3">Abnormal immune checkpoint activation in cHL</span><span class="headingEndMark"> — </span>Abnormal activation of the PD-1 immune checkpoint by multiple mechanisms is critical for T cell immunosuppression and immune evasion by HRS cells. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune checkpoint</strong> – In the normal immune response, PD-1 signaling helps prevent excessive activation of T cells, thereby limiting tissue damage, maintaining immune tolerance, and suppressing the development of autoimmune diseases and allergic reactions [<a href="#rid100">100-102</a>]. PD-1 regulates signaling from the TCR and costimulatory receptors by down-regulating the immune response after disease elimination. Further details of the immune checkpoint and tumor immunology are presented separately. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'Tumor immunology'</a>.)</p><p></p><p class="bulletIndent1">PD-1 is expressed on activated T cells (but not by resting T cells), T regulatory cells (Tregs), T follicular helper cells, natural killer cells, B cells, and macrophages [<a href="#rid100">100,103</a>]. PD-1 has two ligands: PD-L1 and PD-L2. PD-L1 is highly expressed on HRS cells, tumor-infiltrating macrophages, dendritic cells, and certain other malignant cells [<a href="#rid100">100,104</a>]. Binding of ligands to PD-1 cross-links it to the antigen-TCR complex. This leads to recruitment of SHP-2, which dephosphorylates ZAP-70 in T cells and, in turn, attenuates downstream signaling through the phosphatidylinositol 3-kinase (PI3K)/AKT and RAS-MEK-extracellular signal regulated kinase pathways, downregulates TNF alpha and IL-2, and inhibits T cell proliferation [<a href="#rid100">100-102,105,106</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abnormal immune checkpoint activation in cHL</strong> – Overexpression of PD-L1 and PD-L2 contributes to the creation of an immunoprotected niche that is implicated in the "exhaustion" of PD1+ cytotoxic T cells in cHL and enhanced HRS cell survival. </p><p></p><p class="bulletIndent1">Nearly all cases of cHL have alterations of t<em>he PD-L1</em> and/<em>or PD-L2</em> genetic loci [<a href="#rid104">104,107</a>]. Gene amplification or polysomy of chromosome 9p24.1 (the chromosomal locus <em>of PD-L1</em> a<em>nd PD-L2</em>) causes a copy number-dependent increase of protein expression [<a href="#rid107">107</a>]. In addition, the chromosome 9p amplicon almost always includ<em>es JAK2</em>, which further increases PD-1 ligand expression by HRS cells of cHL via the JAK/STAT signaling pathway [<a href="#rid104">104</a>]. HRS cells also transmit local signals that drive expression of PD-L1 on macrophages, and PD-L1+ macrophages co-localize with PD-L1+ HRS to enhance the immunoprotected niche [<a href="#rid108">108</a>]. The microenvironment of cHL also contains an expanded population of T cells that express lymphocyte-activation gene 3 (LAG3), which binds MHC class II proteins and inhibits T cell activation [<a href="#rid109">109</a>]. Expression of certain proteins in EBV-positive HL may also contribute to increased PD-1 ligand expression. (See <a class="local">'Epstein-Barr virus'</a> below.)  </p><p></p><p class="bulletIndent1">The functional importance of PD-1 T cell-dependent immunoevasion by HRS cells of cHL is illustrated by the efficacy of anti-PD-1 monoclonal antibodies in relapsed and refractory cHL, as discussed separately. (See  <a class="medical medical_review" href="/d/html/4765.html" rel="external">"Treatment of relapsed or refractory classic Hodgkin lymphoma", section on 'PD-1 blockade'</a>.) </p><p></p><p class="headingAnchor" id="H1288621802"><span class="h3">Loss of MHC molecule expression</span><span class="headingEndMark"> — </span>Loss of expression of MHC molecules is a common feature of cHL, especially in EBV-negative cases, and may contribute to immune evasion by the HRS cells of cHL [<a href="#rid110">110</a>]. </p><p>Mutations that contribute to loss of HLA expression by the HRS cells of cHL involve:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CIITA </strong>– Gene rearrangements involving <em>CIITA</em>, which encodes a transactivator that regulates MHC class II expression, are found in approximately 15 percent of cHL cases [<a href="#rid111">111</a>]. <em>CIITA</em> rearrangements create fusion genes encoding abnormal factors that decrease MHC class II expression, while also increasing PD-L1 and PD-L2 expression.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta-2 microglobulin</strong> – Beta-2 microglobulin (B2M) forms a heterodimer with MHC class I proteins and is required for their surface expression. In one study, biallelic inactivating mutations of <em>B2M</em> were found in 7 of 10 cases of cHL and caused loss of MHC class I expression [<a href="#rid10">10</a>]. <em>B2M</em> mutations with concordant HLA class I downregulation were also reported in HL cell lines [<a href="#rid112">112</a>].</p><p></p><p class="headingAnchor" id="H2108071948"><span class="h2">Epstein-Barr virus</span><span class="headingEndMark"> — </span>Detection of EBV varies with histologic subtype of HL and patient characteristics. EBV appears to contribute to the pathogenesis of cHL by replacing one or more of the genetic alterations are required for the development of HL.</p><p>The prevalence of EBV ranges from approximately 75 percent in mixed cellularity cHL and lymphocyte-depleted cHL to 10 to 25 percent in nodular sclerosing cHL [<a href="#rid3">3</a>]. By contrast, EBV is detected in only approximately 5 percent in nodular lymphocyte-predominant HL (NLPHL). The prevalence of EBV infection also varies according to age, geography, and immune competence, but is &gt;90 percent in all adult populations worldwide. (See  <a class="medical medical_review" href="/d/html/4691.html" rel="external">"Hodgkin lymphoma: Epidemiology and risk factors", section on 'Epstein-Barr virus'</a>.)</p><p>EBV infection of HRS cells is latent (ie, the virus does not replicate) and the viral genome is carried as an episome (a circular configuration that is physically separate from chromosomal DNA). The clonal nature of EBV in HL indicates that viral infection preceded cellular transformation and clonal expansion. The virology of EBV, including genomic structure, gene products, and the nature of EBV infection and transformation are discussed separately. (See  <a class="medical medical_review" href="/d/html/8276.html" rel="external">"Virology of Epstein-Barr virus"</a>.)</p><p>The precise mechanisms by which EBV contributes to cHL pathogenesis are uncertain, but EBV gene products may replace one of the genetic alterations that are required for the development of HL [<a href="#rid113">113</a>]. EBV-infected tumor cells express a subset of EBV genes, some of which contribute to aberrant signaling, suppression of apoptosis, and immune evasion by HRS cells:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Latent membrane protein 1 (LMP1)</strong> – LMP1 encodes a transmembrane protein that is essential for EBV-mediated lymphocyte immortalization, and constitutive expression of LMP1 is sufficient to induce B cell lymphomas in transgenic mice [<a href="#rid114">114-116</a>]. LMP1 may contribute to HL by several possible mechanisms:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Escape from apoptosis</strong> – LMP1 may enable HRS cells to escape apoptotic destruction in germinal centers (GC). LMP1 resembles CD40 (tumor necrosis factor receptor) and may function like a constitutively activated CD40 molecule [<a href="#rid117">117,118</a>]. Signaling through CD40 can delay apoptosis of B cells in GCs. LMP1 also leads to increased expression of discoidin domain receptor 1 (DDR1), which is commonly overexpressed in HRS cells. DDR1 is a receptor tyrosine kinase that, upon binding with collagen, increases lymphoma cell survival in vitro [<a href="#rid119">119</a>]. (See <a class="local">'Apoptosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Activation of NF-kB</strong> – In HL tumor cell lines, LMP1 activates NF-kB by promoting IkB turnover; constitutive activation of NF-kB is linked to the growth and survival of HRS cells [<a href="#rid120">120</a>]. (See <a class="local">'NF-kB'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>PD-L1 expression</strong> – LMP1 increases expression of PD-L1, which is important for immune evasion, via AP-1 and JAK/STAT pathways [<a href="#rid121">121</a>]. LMP1 also induces expression on HRS cells of CD137, a potent costimulatory molecule that is normally expressed on activated T cells. Aberrant expression of CD137 supports growth of HRS cells and, like PD-L1, leads to escape from immune surveillance. In an HL tissue microarray, 96 percent of the CD137-positive HL cases stained positive for LMP1, providing an additional link between EBV and cHL pathogenesis [<a href="#rid122">122</a>]. (See <a class="local">'Immune evasion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Latent membrane protein 2a (LMP2a)</strong> – LMP2a is an integral membrane protein that co-localizes with LMP1 in the plasma membrane of EBV-infected lymphocytes [<a href="#rid123">123</a>]. LMP2a contains an activation motif that resembles those of Ig molecules. In developing B lymphocytes, a failure to express Ig ordinarily leads to apoptosis, but expression of LMP2a on the cellular membrane produces a constitutive signal that prevents apoptosis of pre-B cells that do not express Ig [<a href="#rid12">12,123-127</a>]. The large majority of cases of HL that carry inactivating Ig mutations are EBV positive, suggesting that EBV infection in HRS cells in the GC microenvironment may protect these cells from apoptosis [<a href="#rid12">12</a>].</p><p></p><p>EBV infection is estimated to have occurred in 90 to 95 percent of adults, yet only a small fraction of infected individuals develops EBV-positive HL. The triggers for HL tumorigenesis in B lymphocytes are poorly defined, but certain environmental factors (eg, age at infection) and genetic factors (eg, certain variations of MHC loci) are associated with higher risk of progressing to EBV-positive cHL, as described separately. (See  <a class="medical medical_review" href="/d/html/4691.html" rel="external">"Hodgkin lymphoma: Epidemiology and risk factors", section on 'Risk factors'</a>.)</p><p class="headingAnchor" id="H601620989"><span class="h1">NODULAR LYMPHOCYTE-PREDOMINANT HL</span><span class="headingEndMark"> — </span>Nodular lymphocyte-predominant HL (NLPHL) accounts for &lt;10 percent of HL.</p><p>The International Consensus Classification (ICC) refers to NLPHL as nodular lymphocyte predominant B-cell lymphoma [<a href="#rid1">1</a>], based on major biological and clinical differences between NLPHL and cHL (eg, retention of functional B cell program in NLPHL and the close relationship of NLPHL with T-cell/histiocyte-rich large B-cell lymphoma) [<a href="#rid128">128</a>]. The 5<sup>th</sup> edition of the World Health Organization Classification of Hematologic Malignancies retained the name NLPHL [<a href="#rid2">2</a>]:</p><p>NLPHL is characterized by scattered neoplastic cells, known as lymphocyte predominant (LP; formerly called lymphocytic and histiocytic variants [L&amp;H cells]), surrounded by an infiltrate of small lymphocytes and other nonmalignant cells. The clinical presentation, pathology, prognosis, diagnosis, and treatment of NLPHL differ significantly from classic HL (cHL), as discussed separately. (See  <a class="medical medical_review" href="/d/html/4730.html" rel="external">"Nodular lymphocyte-predominant Hodgkin lymphoma: Clinical manifestations, diagnosis, and staging"</a> and  <a class="medical medical_review" href="/d/html/4732.html" rel="external">"Treatment of nodular lymphocyte-predominant Hodgkin lymphoma"</a>.) </p><p class="headingAnchor" id="H3378642089"><span class="h2">Microscopy</span><span class="headingEndMark"> — </span>Lymph nodes in NLPHL are partially or totally effaced by an infiltrate of small lymphocytes, histiocytes, epithelioid histiocytes, with intermingled LP cells. NLPHL usually assumes a nodular pattern, but nodular and diffuse or predominantly diffuse patterns are also seen [<a href="#rid129">129</a>]. Unusual cases, which are usually associated with loss of nodularity and increased infiltration by T cells, may have a more aggressive clinical course and can be challenging to distinguish from T-cell/histiocyte rich large B cell lymphoma (THRLBCL). </p><p>The nonmalignant infiltrative component of NLPHL comprises small B lymphocytes, follicular dendritic cells, and follicular CD57+/PD-1+ T lymphocytes, which often form rosettes around the LP cells; the cellular background of NLPHL is less heterogeneous than the polymorphous infiltrate in cHL. (See  <a class="medical medical_review" href="/d/html/4730.html" rel="external">"Nodular lymphocyte-predominant Hodgkin lymphoma: Clinical manifestations, diagnosis, and staging", section on 'Morphology'</a>.)</p><p class="headingAnchor" id="H1465230720"><span class="h2">LP cells</span><span class="headingEndMark"> — </span>The presence of malignant LP cells is required for the diagnosis of NLPHL. LP cells are also called "popcorn cells" because of their distinctive morphology. </p><p>Although both LP cells and Hodgkin/Reed-Sternberg cells (HRS; the malignant counterparts in cHL) are both derived from germinal center (GC) B cells, they differ morphologically, genetically, and phenotypically. (See <a class="local">'Hodgkin/Reed-Sternberg cells'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Morphology</strong> – LP cells have a characteristic irregular, polypoid nuclear morphology (<a class="graphic graphic_picture graphicRef63097" href="/d/graphic/63097.html" rel="external">picture 3</a>) that accounts for the description as popcorn cells. LP cells are readily distinguished from the characteristic binucleate appearance of HRS cells (<a class="graphic graphic_picture graphicRef69090" href="/d/graphic/69090.html" rel="external">picture 2</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunophenotype</strong> – LP cells consistently express CD20 and CD45 but do not express CD30 or CD15 [<a href="#rid130">130</a>]. By contrast, expression of CD30 is a hallmark of HRS cells, which also express CD15, infrequently express CD20, and do not express CD45.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protein and gene expression</strong> – LP cells generally express B lineage proteins, including CD20, BCL6, and PAX5, but are usually negative for CD10 (a characteristic marker of normal GC B cells) [<a href="#rid131">131,132</a>]. The presence of functionally rearranged immunoglobulin genes (<em>IGHV</em>) with a high load of somatic mutations is consistent with the GC B cell origin of LP cells [<a href="#rid33">33,131,133-135</a>].</p><p></p><p class="bulletIndent1">LP cells exhibit activation of nuclear factor kappa B (NF-kB) and increased expression of cytokines, as compared to normal GC B cells [<a href="#rid136">136</a>]. Patterns of gene expression in NLPHL resemble those of cHL and T cell/histiocyte-rich large B cell lymphomas (THRLBCL) (see <a class="local">'Relationship to THRLBCL'</a> below) [<a href="#rid136">136,137</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytogenetics and mutations</strong> – <em>BCL6</em> rearrangements are found in approximately half of NLPHL cases, which contrasts with the lower prevalence in HRS cells [<a href="#rid138">138,139</a>]. Approximately 80 percent of cases have somatic mutations of <em>PAX5</em>, <em>MYC,</em> and other genes [<a href="#rid35">35</a>]. Genome sequencing identified recurrent mutations in the kinase <em>SGK1</em>, the phosphatase <em>DUSP2</em>, and the transcription factor <em>JUNB</em> [<a href="#rid140">140</a>], which are also frequently mutated in THRLBCL [<a href="#rid141">141</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epstein-Barr virus (EBV)</strong> – EBV is detected in a small minority of cases of NLPHL (approximately 5 percent) [<a href="#rid142">142</a>].</p><p></p><p class="headingAnchor" id="H2975938107"><span class="h2">Pathogenesis of NLPHL</span><span class="headingEndMark"> — </span>Both NLPHL and cHL share features of aberrant signaling and immune evasion, but the pathogenic mechanisms of NLPHL are less well-defined. LP cells do not express PD-1 ligands, so the mechanism of immune evasion by NLPHL in the face of abundant effector cells is uncertain. </p><p>Microdissected LP cells of NLPHL exhibit constitutive nuclear factor kappa B (NF-kB) activity, aberrant extracellular signal-regulated kinase (ERK) signaling, an anti-apoptotic phenotype, and partial loss of the B cell phenotype [<a href="#rid136">136</a>]. Gene expression by LP cells resembles that of cHL and THRLBCL and is consistent with the origin of LP cells arising from GC B cells at the transition to memory B cells. </p><p>Pathogenic mechanisms that contribute to HL are discussed separately. (See <a class="local">'Pathogenesis of cHL'</a> above.)</p><p class="headingAnchor" id="H3044079491"><span class="h2">Relationship to THRLBCL</span><span class="headingEndMark"> — </span>T cell/histiocyte-rich large B cell lymphoma (THRLBCL) is an aggressive B cell lymphoma [<a href="#rid3">3</a>]. NLPHL and THRLBCL share biologic and clinical features, and NLPHL can undergo THRLBCL-like transformation. It has been speculated that THRLBCL may represent a diffuse variant or an extension of NLPHL.</p><p>NLPHL (especially cases with a diffuse growth pattern) can resemble the microscopic appearance of THRLBCL, and NLPHL can undergo THRLBCL-like transformation that is indistinguishable from primary THRLBCL [<a href="#rid143">143-145</a>]. </p><p>NLPHL and THRLBCL also share molecular and immunophenotypic features; they appear to differ primarily in the cellular composition of the tumor microenvironment. Tumor cells of NLPHL and THRLBCL have similar patterns of gene expression, mutation profiles, and deregulation of apoptosis-associated genes and both exhibit partial loss of the B cell phenotype [<a href="#rid136">136,137,146</a>]. In contrast with the B cell-rich nodules associated with follicular dendritic cell meshworks and rosetting T cells of NLPHL, the THRLBCL cellular milieu has a high content of non-rosetting T cells, macrophages, and dendritic cells [<a href="#rid147">147</a>].</p><p class="headingAnchor" id="H14589362"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Hodgkin lymphoma (HL) is characterized by relatively small numbers of malignant cells admixed with an abundant infiltrate of immune effector and inflammatory cells. The broad category of HL includes (see <a class="local">'Overview of Hodgkin lymphoma'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Classic HL (cHL), which accounts for &gt;90 of HL </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nodular lymphocyte-predominant HL (NLPHL)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classic Hodgkin lymphoma (cHL)</strong> – In cHL, the lymph node architecture is effaced by an infiltrate of scarce malignant cells admixed with an abundance of nonmalignant inflammatory and immune effector cells and a variable degree of fibrosis (<a class="graphic graphic_picture graphicRef54520" href="/d/graphic/54520.html" rel="external">picture 1</a>).</p><p></p><p class="bulletIndent1">Hodgkin/Reed-Sternberg (HRS) cells are the malignant cells of cHL and are typically binucleate (<a class="graphic graphic_picture graphicRef69090" href="/d/graphic/69090.html" rel="external">picture 2</a>). HRS cells are derived from germinal center (GC) B cells, but they have lost the characteristic immunophenotype and gene expression of normal B cells. HRS cells have constitutively activated nuclear factor kappa B (NF-kB), increased extracellular signal-regulated kinase (ERK) signaling, and immune checkpoint abnormalities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis of cHL</strong> – Mechanisms that contribute to the pathogenesis of cHL include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mutations</strong> - Mutations that transform B lymphocytes as they are undergoing maturation. (See <a class="local">'Cytogenetics and mutations'</a> above and <a class="local">'Cellular origin of HRS cells'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Aberrant signaling</strong> - Aberrant autocrine and paracrine signaling by HRS cells (eg, NF-kB, JAK-STAT) that attracts inflammatory cells, which in turn support the proliferation and survival of HRS cells. (See <a class="local">'Aberrant signaling'</a> above and <a class="local">'Apoptosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gene amplification</strong> - Amplification of genes associated with chromosome 9p24.1 led to deregulation of at least four genes (<em>JAK2, JMJD2C, PDL1</em>, and <em>PDL2</em>) that are important in the pathogenesis of HL. (See <a class="local">'Cytogenetics and mutations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immune escape</strong> - Protection of the malignant cells from immune destruction. (See <a class="local">'Immune evasion'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Epstein-Barr virus (EBV)</strong> EBV is detected in a subset of cHL cells and it contributes to pathogenesis by augmenting growth and/or inhibiting apoptosis. (See <a class="local">'Epstein-Barr virus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) </strong>– NLPHL, which accounts for 5 to 10 percent of HL, differs from cHL by demographics, clinical presentation, immunophenotype, natural history, and management. This subtype is called nodular lymphocyte predominant B-cell lymphoma by the International Consensus Classification (ICC), whereas the term NLPHL is retained in the WHO 5<sup>th</sup> edition classification. (See <a class="local">'Nodular lymphocyte-predominant HL'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Microscopy</strong> - NLPHL is characterized by scattered neoplastic cells, known as lymphocyte predominant (LP) cells (also called popcorn cells or L&amp;H cells) that are surrounded by a nodular infiltrate of small lymphocytes and other nonmalignant cells. (See <a class="local">'Microscopy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>LP cells</strong> - Although both LP cells and HRS cells are derived from GC B cells, they differ morphologically, genetically, and phenotypically. (See <a class="local">'LP cells'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pathogenesis</strong> - NLPHL shares with cHL features of aberrant signaling (eg, NF-kB), an antiapoptotic phenotype, and partial loss of the B cell phenotype, but the pathogenesis of NLPHL is less well-defined. (See <a class="local">'Pathogenesis of NLPHL'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022; 140:1229.</a></li><li><a class="nounderline abstract_t">Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36:1720.</a></li><li class="breakAll">WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.</li><li><a class="nounderline abstract_t">Rengstl B, Newrzela S, Heinrich T, et al. Incomplete cytokinesis and re-fusion of small mononucleated Hodgkin cells lead to giant multinucleated Reed-Sternberg cells. Proc Natl Acad Sci U S A 2013; 110:20729.</a></li><li><a class="nounderline abstract_t">Xavier de Carvalho A, Maiato H, Maia AF, et al. Reed-Sternberg cells form by abscission failure in the presence of functional Aurora B kinase. PLoS One 2015; 10:e0124629.</a></li><li><a class="nounderline abstract_t">Tzankov A, Zimpfer A, Pehrs AC, et al. Expression of B-cell markers in classical hodgkin lymphoma: a tissue microarray analysis of 330 cases. Mod Pathol 2003; 16:1141.</a></li><li><a class="nounderline abstract_t">Falini B, Bigerna B, Pasqualucci L, et al. Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease. Blood 1996; 87:465.</a></li><li><a class="nounderline abstract_t">Schwering I, Bräuninger A, Klein U, et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003; 101:1505.</a></li><li><a class="nounderline abstract_t">Marafioti T, Hummel M, Foss HD, et al. Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 2000; 95:1443.</a></li><li><a class="nounderline abstract_t">Reichel J, Chadburn A, Rubinstein PG, et al. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood 2015; 125:1061.</a></li><li><a class="nounderline abstract_t">Kanzler H, Küppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996; 184:1495.</a></li><li><a class="nounderline abstract_t">Bräuninger A, Schmitz R, Bechtel D, et al. Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma. Int J Cancer 2006; 118:1853.</a></li><li><a class="nounderline abstract_t">Ushmorov A, Leithäuser F, Sakk O, et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood 2006; 107:2493.</a></li><li><a class="nounderline abstract_t">Ushmorov A, Ritz O, Hummel M, et al. Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression. Blood 2004; 104:3326.</a></li><li><a class="nounderline abstract_t">Doerr JR, Malone CS, Fike FM, et al. Patterned CpG methylation of silenced B cell gene promoters in classical Hodgkin lymphoma-derived and primary effusion lymphoma cell lines. J Mol Biol 2005; 350:631.</a></li><li><a class="nounderline abstract_t">Rui L, Emre NC, Kruhlak MJ, et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 2010; 18:590.</a></li><li><a class="nounderline abstract_t">Mathas S, Hinz M, Anagnostopoulos I, et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 2002; 21:4104.</a></li><li><a class="nounderline abstract_t">Stein H, Marafioti T, Foss HD, et al. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 2001; 97:496.</a></li><li><a class="nounderline abstract_t">Theil J, Laumen H, Marafioti T, et al. Defective octamer-dependent transcription is responsible for silenced immunoglobulin transcription in Reed-Sternberg cells. Blood 2001; 97:3191.</a></li><li><a class="nounderline abstract_t">Jundt F, Kley K, Anagnostopoulos I, et al. Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. Blood 2002; 99:3060.</a></li><li><a class="nounderline abstract_t">Schmitz R, Stanelle J, Hansmann ML, Küppers R. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol 2009; 4:151.</a></li><li><a class="nounderline abstract_t">Mathas S, Janz M, Hummel F, et al. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol 2006; 7:207.</a></li><li><a class="nounderline abstract_t">Renné C, Martin-Subero JI, Eickernjäger M, et al. Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin's lymphoma. Am J Pathol 2006; 169:655.</a></li><li><a class="nounderline abstract_t">Scheeren FA, Diehl SA, Smit LA, et al. IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis. Blood 2008; 111:4706.</a></li><li><a class="nounderline abstract_t">Wein F, Otto T, Lambertz P, et al. Potential role of hypoxia in early stages of Hodgkin lymphoma pathogenesis. Haematologica 2015; 100:1320.</a></li><li><a class="nounderline abstract_t">Bohle V, Döring C, Hansmann ML, Küppers R. Role of early B-cell factor 1 (EBF1) in Hodgkin lymphoma. Leukemia 2013; 27:671.</a></li><li><a class="nounderline abstract_t">Tiacci E, Döring C, Brune V, et al. Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. Blood 2012; 120:4609.</a></li><li><a class="nounderline abstract_t">Weber-Matthiesen K, Deerberg J, Poetsch M, et al. Numerical chromosome aberrations are present within the CD30+ Hodgkin and Reed-Sternberg cells in 100% of analyzed cases of Hodgkin's disease. Blood 1995; 86:1464.</a></li><li><a class="nounderline abstract_t">Deerberg-Wittram J, Weber-Matthiesen K, Schlegelberger B. Cytogenetics and molecular cytogenetics in Hodgkin's disease. Ann Oncol 1996; 7 Suppl 4:49.</a></li><li><a class="nounderline abstract_t">Steidl C, Telenius A, Shah SP, et al. Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood 2010; 116:418.</a></li><li><a class="nounderline abstract_t">Küppers R, Schwering I, Bräuninger A, et al. Biology of Hodgkin's lymphoma. Ann Oncol 2002; 13 Suppl 1:11.</a></li><li><a class="nounderline abstract_t">Jacob J, Kelsoe G, Rajewsky K, Weiss U. Intraclonal generation of antibody mutants in germinal centres. Nature 1991; 354:389.</a></li><li><a class="nounderline abstract_t">Marafioti T, Hummel M, Anagnostopoulos I, et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med 1997; 337:453.</a></li><li><a class="nounderline abstract_t">Bräuninger A, Wacker HH, Rajewsky K, et al. Typing the histogenetic origin of the tumor cells of lymphocyte-rich classical Hodgkin's lymphoma in relation to tumor cells of classical and lymphocyte-predominance Hodgkin's lymphoma. Cancer Res 2003; 63:1644.</a></li><li><a class="nounderline abstract_t">Liso A, Capello D, Marafioti T, et al. Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. Blood 2006; 108:1013.</a></li><li><a class="nounderline abstract_t">Thomas RK, Re D, Wolf J, Diehl V. Part I: Hodgkin's lymphoma--molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol 2004; 5:11.</a></li><li><a class="nounderline abstract_t">Marafioti T, Hummel M, Anagnostopoulos I, et al. Classical Hodgkin's disease and follicular lymphoma originating from the same germinal center B cell. J Clin Oncol 1999; 17:3804.</a></li><li><a class="nounderline abstract_t">Bräuninger A, Hansmann ML, Strickler JG, et al. Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma. N Engl J Med 1999; 340:1239.</a></li><li><a class="nounderline abstract_t">Ohno T, Smir BN, Weisenburger DD, et al. Origin of the Hodgkin/Reed-Sternberg cells in chronic lymphocytic leukemia with "Hodgkin's transformation". Blood 1998; 91:1757.</a></li><li><a class="nounderline abstract_t">Seitz V, Hummel M, Marafioti T, et al. Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease. Blood 2000; 95:3020.</a></li><li><a class="nounderline abstract_t">Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16:225.</a></li><li><a class="nounderline abstract_t">Liou HC, Sha WC, Scott ML, Baltimore D. Sequential induction of NF-kappa B/Rel family proteins during B-cell terminal differentiation. Mol Cell Biol 1994; 14:5349.</a></li><li><a class="nounderline abstract_t">Miyamoto S, Schmitt MJ, Verma IM. Qualitative changes in the subunit composition of kappa B-binding complexes during murine B-cell differentiation. Proc Natl Acad Sci U S A 1994; 91:5056.</a></li><li><a class="nounderline abstract_t">Joos S, Menz CK, Wrobel G, et al. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood 2002; 99:1381.</a></li><li><a class="nounderline abstract_t">Emmerich F, Meiser M, Hummel M, et al. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 1999; 94:3129.</a></li><li><a class="nounderline abstract_t">Cabannes E, Khan G, Aillet F, et al. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene 1999; 18:3063.</a></li><li><a class="nounderline abstract_t">Jungnickel B, Staratschek-Jox A, Bräuninger A, et al. Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. J Exp Med 2000; 191:395.</a></li><li><a class="nounderline abstract_t">Martín-Subero JI, Gesk S, Harder L, et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood 2002; 99:1474.</a></li><li><a class="nounderline abstract_t">Mathas S, Hartmann S, Küppers R. Hodgkin lymphoma: Pathology and biology. Semin Hematol 2016; 53:139.</a></li><li><a class="nounderline abstract_t">Emmerich F, Theurich S, Hummel M, et al. Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells. J Pathol 2003; 201:413.</a></li><li><a class="nounderline abstract_t">Schmitz R, Hansmann ML, Bohle V, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009; 206:981.</a></li><li><a class="nounderline abstract_t">Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009; 459:712.</a></li><li><a class="nounderline abstract_t">Weniger MA, Küppers R. NF-κB deregulation in Hodgkin lymphoma. Semin Cancer Biol 2016; 39:32.</a></li><li><a class="nounderline abstract_t">Sun SC, Ganchi PA, Ballard DW, Greene WC. NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. Science 1993; 259:1912.</a></li><li><a class="nounderline abstract_t">Scott ML, Fujita T, Liou HC, et al. The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms. Genes Dev 1993; 7:1266.</a></li><li><a class="nounderline abstract_t">Buri C, Körner M, Schärli P, et al. CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the nonneoplastic leukocytic infiltrates of Hodgkin disease. Blood 2001; 97:1543.</a></li><li><a class="nounderline abstract_t">Küppers R, Engert A, Hansmann ML. Hodgkin lymphoma. J Clin Invest 2012; 122:3439.</a></li><li><a class="nounderline abstract_t">Zahn M, Marienfeld R, Melzner I, et al. A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells. Blood 2017; 129:1480.</a></li><li><a class="nounderline abstract_t">Skinnider BF, Elia AJ, Gascoyne RD, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2002; 99:618.</a></li><li><a class="nounderline abstract_t">Hinz M, Lemke P, Anagnostopoulos I, et al. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 2002; 196:605.</a></li><li><a class="nounderline abstract_t">Joos S, Küpper M, Ohl S, et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 2000; 60:549.</a></li><li><a class="nounderline abstract_t">Weniger MA, Melzner I, Menz CK, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 2006; 25:2679.</a></li><li><a class="nounderline abstract_t">Gunawardana J, Chan FC, Telenius A, et al. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat Genet 2014; 46:329.</a></li><li><a class="nounderline abstract_t">Jundt F, Anagnostopoulos I, Förster R, et al. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 2002; 99:3398.</a></li><li><a class="nounderline abstract_t">Schwarzer R, Dörken B, Jundt F. Notch is an essential upstream regulator of NF-κB and is relevant for survival of Hodgkin and Reed-Sternberg cells. Leukemia 2012; 26:806.</a></li><li><a class="nounderline abstract_t">Pui JC, Allman D, Xu L, et al. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity 1999; 11:299.</a></li><li><a class="nounderline abstract_t">Kapp U, Yeh WC, Patterson B, et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 1999; 189:1939.</a></li><li><a class="nounderline abstract_t">Skinnider BF, Elia AJ, Gascoyne RD, et al. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2001; 97:250.</a></li><li><a class="nounderline abstract_t">Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002; 99:4283.</a></li><li><a class="nounderline abstract_t">Chomarat P, Banchereau J. Interleukin-4 and interleukin-13: their similarities and discrepancies. Int Rev Immunol 1998; 17:1.</a></li><li><a class="nounderline abstract_t">Manna SK, Aggarwal BB. IL-13 suppresses TNF-induced activation of nuclear factor-kappa B, activation protein-1, and apoptosis. J Immunol 1998; 161:2863.</a></li><li><a class="nounderline abstract_t">Lentsch AB, Shanley TP, Sarma V, Ward PA. In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J Clin Invest 1997; 100:2443.</a></li><li><a class="nounderline abstract_t">Krappmann D, Emmerich F, Kordes U, et al. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999; 18:943.</a></li><li><a class="nounderline abstract_t">Takeda K, Kamanaka M, Tanaka T, et al. Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice. J Immunol 1996; 157:3220.</a></li><li><a class="nounderline abstract_t">Iciek LA, Delphin SA, Stavnezer J. CD40 cross-linking induces Ig epsilon germline transcripts in B cells via activation of NF-kappaB: synergy with IL-4 induction. J Immunol 1997; 158:4769.</a></li><li><a class="nounderline abstract_t">Shen CH, Stavnezer J. Interaction of stat6 and NF-kappaB: direct association and synergistic activation of interleukin-4-induced transcription. Mol Cell Biol 1998; 18:3395.</a></li><li><a class="nounderline abstract_t">Messner B, Stütz AM, Albrecht B, et al. Cooperation of binding sites for STAT6 and NF kappa B/rel in the IL-4-induced up-regulation of the human IgE germline promoter. J Immunol 1997; 159:3330.</a></li><li><a class="nounderline abstract_t">Ikushima S, Inukai T, Inaba T, et al. Pivotal role for the NFIL3/E4BP4 transcription factor in interleukin 3-mediated survival of pro-B lymphocytes. Proc Natl Acad Sci U S A 1997; 94:2609.</a></li><li><a class="nounderline abstract_t">Alizadeh A, Eisen M, Botstein D, et al. Probing lymphocyte biology by genomic-scale gene expression analysis. J Clin Immunol 1998; 18:373.</a></li><li><a class="nounderline abstract_t">Chu CC, Paul WE. Expressed genes in interleukin-4 treated B cells identified by cDNA representational difference analysis. Mol Immunol 1998; 35:487.</a></li><li><a class="nounderline abstract_t">Liu WR, Shipp MA. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Blood 2017; 130:2265.</a></li><li><a class="nounderline abstract_t">Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 2008; 26:535.</a></li><li><a class="nounderline abstract_t">Kreher S, Bouhlel MA, Cauchy P, et al. Mapping of transcription factor motifs in active chromatin identifies IRF5 as key regulator in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A 2014; 111:E4513.</a></li><li><a class="nounderline abstract_t">Janz M, Hummel M, Truss M, et al. Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3), which promotes viability of Hodgkin/Reed-Sternberg cells. Blood 2006; 107:2536.</a></li><li><a class="nounderline abstract_t">Watanabe M, Ogawa Y, Itoh K, et al. Hypomethylation of CD30 CpG islands with aberrant JunB expression drives CD30 induction in Hodgkin lymphoma and anaplastic large cell lymphoma. Lab Invest 2008; 88:48.</a></li><li><a class="nounderline abstract_t">Gause A, Keymis S, Scholz R, et al. Increased levels of circulating cytokines in patients with untreated Hodgkin's disease. Lymphokine Cytokine Res 1992; 11:109.</a></li><li><a class="nounderline abstract_t">Küpper M, Joos S, von Bonin F, et al. MDM2 gene amplification and lack of p53 point mutations in Hodgkin and Reed-Sternberg cells: results from single-cell polymerase chain reaction and molecular cytogenetic studies. Br J Haematol 2001; 112:768.</a></li><li><a class="nounderline abstract_t">Aldinucci D, Lorenzon D, Cattaruzza L, et al. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer 2008; 122:769.</a></li><li><a class="nounderline abstract_t">Fhu CW, Graham AM, Yap CT, et al. Reed-Sternberg cell-derived lymphotoxin-α activates endothelial cells to enhance T-cell recruitment in classical Hodgkin lymphoma. Blood 2014; 124:2973.</a></li><li><a class="nounderline abstract_t">Weniger MA, Küppers R. Molecular biology of Hodgkin lymphoma. Leukemia 2021; 35:968.</a></li><li><a class="nounderline abstract_t">Samoszuk M, Nansen L. Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. Blood 1990; 75:13.</a></li><li><a class="nounderline abstract_t">Hanamoto H, Nakayama T, Miyazato H, et al. Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin's disease with frequent infiltration of eosinophils and/or plasma cells. Am J Pathol 2004; 164:997.</a></li><li><a class="nounderline abstract_t">Jundt F, Anagnostopoulos I, Bommert K, et al. Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood 1999; 94:2065.</a></li><li><a class="nounderline abstract_t">Kadin ME, Agnarsson BA, Ellingsworth LR, Newcom SR. Immunohistochemical evidence of a role for transforming growth factor beta in the pathogenesis of nodular sclerosing Hodgkin's disease. Am J Pathol 1990; 136:1209.</a></li><li><a class="nounderline abstract_t">Hsu SM, Lin J, Xie SS, et al. Abundant expression of transforming growth factor-beta 1 and -beta 2 by Hodgkin's Reed-Sternberg cells and by reactive T lymphocytes in Hodgkin's disease. Hum Pathol 1993; 24:249.</a></li><li><a class="nounderline abstract_t">Abrams J, Pearl P, Moody M, Schimpff SC. Epithelioid granulomas revisited: long-term follow-up in Hodgkin's disease. Am J Clin Oncol 1988; 11:456.</a></li><li><a class="nounderline abstract_t">O'Connell MJ, Schimpff SC, Kirschner RH, et al. Epithelioid granulomas in Hodgkin disease. A favorable prognostic sign? JAMA 1975; 233:886.</a></li><li><a class="nounderline abstract_t">Kadin ME, Donaldson SS, Dorfman RF. Isolated granulomas in Hodgkin's disease. N Engl J Med 1970; 283:859.</a></li><li><a class="nounderline abstract_t">Al-Maghrabi JA, Sawan AS, Kanaan HD. Hodgkin's lymphoma with exuberant granulomatous reaction. Saudi Med J 2006; 27:1905.</a></li><li><a class="nounderline abstract_t">Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH. Coinhibitory Pathways in Immunotherapy for Cancer. Annu Rev Immunol 2016; 34:539.</a></li><li><a class="nounderline abstract_t">Boussiotis VA. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N Engl J Med 2016; 375:1767.</a></li><li><a class="nounderline abstract_t">Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26:677.</a></li><li><a class="nounderline abstract_t">Gordon SR, Maute RL, Dulken BW, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 2017; 545:495.</a></li><li><a class="nounderline abstract_t">Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116:3268.</a></li><li><a class="nounderline abstract_t">Chemnitz JM, Parry RV, Nichols KE, et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 2004; 173:945.</a></li><li><a class="nounderline abstract_t">Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, et al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med 2012; 209:1201.</a></li><li><a class="nounderline abstract_t">Roemer MG, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. J Clin Oncol 2016; 34:2690.</a></li><li><a class="nounderline abstract_t">Carey CD, Gusenleitner D, Lipschitz M, et al. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood 2017; 130:2420.</a></li><li><a class="nounderline abstract_t">Aoki T, Chong LC, Takata K, et al. Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma. Cancer Discov 2020; 10:406.</a></li><li><a class="nounderline abstract_t">Diepstra A, Poppema S, Boot M, et al. HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma. Tissue Antigens 2008; 71:219.</a></li><li><a class="nounderline abstract_t">Steidl C, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011; 471:377.</a></li><li><a class="nounderline abstract_t">Liu Y, Abdul Razak FR, Terpstra M, et al. The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing. Leukemia 2014; 28:2248.</a></li><li><a class="nounderline abstract_t">Renné C, Hinsch N, Willenbrock K, et al. The aberrant coexpression of several receptor tyrosine kinases is largely restricted to EBV-negative cases of classical Hodgkin's lymphoma. Int J Cancer 2007; 120:2504.</a></li><li><a class="nounderline abstract_t">Kilger E, Kieser A, Baumann M, Hammerschmidt W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J 1998; 17:1700.</a></li><li><a class="nounderline abstract_t">Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985; 313:812.</a></li><li><a class="nounderline abstract_t">Kulwichit W, Edwards RH, Davenport EM, et al. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci U S A 1998; 95:11963.</a></li><li><a class="nounderline abstract_t">MacLennan IC. Germinal centers. Annu Rev Immunol 1994; 12:117.</a></li><li><a class="nounderline abstract_t">Jarrett RF, MacKenzie J. Epstein-Barr virus and other candidate viruses in the pathogenesis of Hodgkin's disease. Semin Hematol 1999; 36:260.</a></li><li><a class="nounderline abstract_t">Cader FZ, Vockerodt M, Bose S, et al. The EBV oncogene LMP1 protects lymphoma cells from cell death through the collagen-mediated activation of DDR1. Blood 2013; 122:4237.</a></li><li><a class="nounderline abstract_t">Sylla BS, Hung SC, Davidson DM, et al. Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-kappaB through a pathway that includes the NF-kappaB-inducing kinase and the IkappaB kinases IKKalpha and IKKbeta. Proc Natl Acad Sci U S A 1998; 95:10106.</a></li><li><a class="nounderline abstract_t">Green MR, Rodig S, Juszczynski P, et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res 2012; 18:1611.</a></li><li><a class="nounderline abstract_t">Aravinth SP, Rajendran S, Li Y, et al. Epstein-Barr virus-encoded LMP1 induces ectopic CD137 expression on Hodgkin and Reed-Sternberg cells via the PI3K-AKT-mTOR pathway. Leuk Lymphoma 2019; 60:2697.</a></li><li><a class="nounderline abstract_t">Mancao C, Hammerschmidt W. Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood 2007; 110:3715.</a></li><li><a class="nounderline abstract_t">Merchant M, Caldwell RG, Longnecker R. The LMP2A ITAM is essential for providing B cells with development and survival signals in vivo. J Virol 2000; 74:9115.</a></li><li><a class="nounderline abstract_t">Murray PG, Constandinou CM, Crocker J, et al. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. Blood 1998; 92:2477.</a></li><li><a class="nounderline abstract_t">Bechtel D, Kurth J, Unkel C, Küppers R. Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas. Blood 2005; 106:4345.</a></li><li><a class="nounderline abstract_t">Chaganti S, Bell AI, Pastor NB, et al. Epstein-Barr virus infection in vitro can rescue germinal center B cells with inactivated immunoglobulin genes. Blood 2005; 106:4249.</a></li><li><a class="nounderline abstract_t">Falini B, Martino G, Lazzi S. A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas. Leukemia 2023; 37:18.</a></li><li><a class="nounderline abstract_t">Fan Z, Natkunam Y, Bair E, et al. Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 2003; 27:1346.</a></li><li><a class="nounderline abstract_t">Nogová L, Reineke T, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008; 26:434.</a></li><li><a class="nounderline abstract_t">Fromm JR, Thomas A, Wood BL. Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting. Am J Pathol 2017; 187:304.</a></li><li><a class="nounderline abstract_t">Uherova P, Valdez R, Ross CW, et al. Nodular lymphocyte predominant Hodgkin lymphoma. An immunophenotypic reappraisal based on a single-institution experience. Am J Clin Pathol 2003; 119:192.</a></li><li><a class="nounderline abstract_t">Braeuninger A, Küppers R, Strickler JG, et al. Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci U S A 1997; 94:9337.</a></li><li><a class="nounderline abstract_t">Ohno T, Stribley JA, Wu G, et al. Clonality in nodular lymphocyte-predominant Hodgkin's disease. N Engl J Med 1997; 337:459.</a></li><li><a class="nounderline abstract_t">Prakash S, Fountaine T, Raffeld M, et al. IgD positive L&amp;H cells identify a unique subset of nodular lymphocyte predominant Hodgkin lymphoma. Am J Surg Pathol 2006; 30:585.</a></li><li><a class="nounderline abstract_t">Brune V, Tiacci E, Pfeil I, et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med 2008; 205:2251.</a></li><li><a class="nounderline abstract_t">Hartmann S, Döring C, Jakobus C, et al. Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma--endpoints of a spectrum of one disease? PLoS One 2013; 8:e78812.</a></li><li><a class="nounderline abstract_t">Wlodarska I, Nooyen P, Maes B, et al. Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma. Blood 2003; 101:706.</a></li><li><a class="nounderline abstract_t">Renné C, Martín-Subero JI, Hansmann ML, Siebert R. Molecular cytogenetic analyses of immunoglobulin loci in nodular lymphocyte predominant Hodgkin's lymphoma reveal a recurrent IGH-BCL6 juxtaposition. J Mol Diagn 2005; 7:352.</a></li><li><a class="nounderline abstract_t">Hartmann S, Schuhmacher B, Rausch T, et al. Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma. Leukemia 2016; 30:844.</a></li><li><a class="nounderline abstract_t">Schuhmacher B, Bein J, Rausch T, et al. JUNB, DUSP2, SGK1, SOCS1 and CREBBP are frequently mutated in T-cell/histiocyte-rich large B-cell lymphoma. Haematologica 2019; 104:330.</a></li><li><a class="nounderline abstract_t">Huppmann AR, Nicolae A, Slack GW, et al. EBV may be expressed in the LP cells of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in both children and adults. Am J Surg Pathol 2014; 38:316.</a></li><li><a class="nounderline abstract_t">Al-Mansour M, Connors JM, Gascoyne RD, et al. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol 2010; 28:793.</a></li><li><a class="nounderline abstract_t">Kenderian SS, Habermann TM, Macon WR, et al. Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution. Blood 2016; 127:1960.</a></li><li><a class="nounderline abstract_t">Biasoli I, Stamatoullas A, Meignin V, et al. Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group. Cancer 2010; 116:631.</a></li><li><a class="nounderline abstract_t">Hartmann S, Döring C, Vucic E, et al. Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma. Br J Haematol 2015; 169:415.</a></li><li><a class="nounderline abstract_t">Van Loo P, Tousseyn T, Vanhentenrijk V, et al. T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response. Haematologica 2010; 95:440.</a></li></ol></div><div id="topicVersionRevision">Topic 4698 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35653592" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35732829" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35732829" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24302766" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Incomplete cytokinesis and re-fusion of small mononucleated Hodgkin cells lead to giant multinucleated Reed-Sternberg cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25933052" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Reed-Sternberg cells form by abscission failure in the presence of functional Aurora B kinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14614054" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Expression of B-cell markers in classical hodgkin lymphoma: a tissue microarray analysis of 330 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8555467" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393731" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10666223" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25488972" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8879220" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16385563" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16304050" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15284123" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15967459" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Patterned CpG methylation of silenced B cell gene promoters in classical Hodgkin lymphoma-derived and primary effusion lymphoma cell lines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21156283" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cooperative epigenetic modulation by cancer amplicon genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12145210" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11154228" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11342448" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Defective octamer-dependent transcription is responsible for silenced immunoglobulin transcription in Reed-Sternberg cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11929801" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19400691" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16369535" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16877363" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18296629" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26160878" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Potential role of hypoxia in early stages of Hodgkin lymphoma pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23174882" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Role of early B-cell factor 1 (EBF1) in Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22955914" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7632954" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Numerical chromosome aberrations are present within the CD30+ Hodgkin and Reed-Sternberg cells in 100% of analyzed cases of Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8836410" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cytogenetics and molecular cytogenetics in Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20339089" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12078890" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Biology of Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1956400" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Intraclonal generation of antibody mutants in germinal centres.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9250847" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12670918" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Typing the histogenetic origin of the tumor cells of lymphocyte-rich classical Hodgkin's lymphoma in relation to tumor cells of classical and lymphocyte-predominance Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16614247" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14700604" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Part I: Hodgkin's lymphoma--molecular biology of Hodgkin and Reed-Sternberg cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10577852" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Classical Hodgkin's disease and follicular lymphoma originating from the same germinal center B cell.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10210707" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9473243" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Origin of the Hodgkin/Reed-Sternberg cells in chronic lymphocytic leukemia with "Hodgkin's transformation".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10807764" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9597130" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8035813" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Sequential induction of NF-kappa B/Rel family proteins during B-cell terminal differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8197184" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Qualitative changes in the subunit composition of kappa B-binding complexes during murine B-cell differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11830490" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10556199" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10340377" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10637284" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11830502" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27496304" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Hodgkin lymphoma: Pathology and biology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14595753" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19380639" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19412163" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Frequent inactivation of A20 in B-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27221964" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : NF-κB deregulation in Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8096091" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8319912" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11238088" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the nonneoplastic leukocytic infiltrates of Hodgkin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23023715" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28082443" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11781246" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12208876" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10676635" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16532038" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24531327" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11964309" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21946908" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Notch is an essential upstream regulator of NF-κB and is relevant for survival of Hodgkin and Reed-Sternberg cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10514008" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Notch1 expression in early lymphopoiesis influences B versus T lineage determination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10377189" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11133768" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12036854" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The role of cytokines in classical Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9914942" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Interleukin-4 and interleukin-13: their similarities and discrepancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9743347" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : IL-13 suppresses TNF-induced activation of nuclear factor-kappa B, activation protein-1, and apoptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9366558" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10023670" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8871614" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9144491" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : CD40 cross-linking induces Ig epsilon germline transcripts in B cells via activation of NF-kappaB: synergy with IL-4 induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9584180" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Interaction of stat6 and NF-kappaB: direct association and synergistic activation of interleukin-4-induced transcription.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9317131" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Cooperation of binding sites for STAT6 and NF kappa B/rel in the IL-4-induced up-regulation of the human IgE germline promoter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9122243" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Pivotal role for the NFIL3/E4BP4 transcription factor in interleukin 3-mediated survival of pro-B lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9857281" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Probing lymphocyte biology by genomic-scale gene expression analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9798653" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Expressed genes in interleukin-4 treated B cells identified by cDNA representational difference analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29167175" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18303999" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The IRF family transcription factors in immunity and oncogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25288773" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Mapping of transcription factor motifs in active chromatin identifies IRF5 as key regulator in classical Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16263788" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3), which promotes viability of Hodgkin/Reed-Sternberg cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17965727" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Hypomethylation of CD30 CpG islands with aberrant JunB expression drives CD30 induction in Hodgkin lymphoma and anaplastic large cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1581417" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Increased levels of circulating cytokines in patients with untreated Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11260082" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : MDM2 gene amplification and lack of p53 point mutations in Hodgkin and Reed-Sternberg cells: results from single-cell polymerase chain reaction and molecular cytogenetic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17935139" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25139349" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Reed-Sternberg cell-derived lymphotoxin-αactivates endothelial cells to enhance T-cell recruitment in classical Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33686198" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Molecular biology of Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2403816" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14982853" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin's disease with frequent infiltration of eosinophils and/or plasma cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10477736" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2356855" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Immunohistochemical evidence of a role for transforming growth factor beta in the pathogenesis of nodular sclerosing Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7681031" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Abundant expression of transforming growth factor-beta 1 and -beta 2 by Hodgkin's Reed-Sternberg cells and by reactive T lymphocytes in Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3407625" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Epithelioid granulomas revisited: long-term follow-up in Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/168415" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Epithelioid granulomas in Hodgkin disease. A favorable prognostic sign?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5458036" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Isolated granulomas in Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17143374" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Hodgkin's lymphoma with exuberant granulomatous reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26927206" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Coinhibitory Pathways in Immunotherapy for Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27806234" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18173375" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : PD-1 and its ligands in tolerance and immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28514441" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20628145" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15240681" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22641383" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27069084" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28893733" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31857391" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18257895" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21368758" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24947018" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17330841" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : The aberrant coexpression of several receptor tyrosine kinases is largely restricted to EBV-negative cases of classical Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9501091" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2983224" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9751773" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8011279" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Germinal centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10462326" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Epstein-Barr virus and other candidate viruses in the pathogenesis of Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24136166" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : The EBV oncogene LMP1 protects lymphoma cells from cell death through the collagen-mediated activation of DDR1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9707608" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-kappaB through a pathway that includes the NF-kappaB-inducing kinase and the IkappaB kinases IKKalpha and IKKbeta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22271878" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31058559" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Epstein-Barr virus-encoded LMP1 induces ectopic CD137 expression on Hodgkin and Reed-Sternberg cells via the PI3K-AKT-mTOR pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17682125" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10982358" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : The LMP2A ITAM is essential for providing B cells with development and survival signals in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9746788" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16131568" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16123211" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Epstein-Barr virus infection in vitro can rescue germinal center B cells with inactivated immunoglobulin genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36460764" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14508396" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18086799" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27998726" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12579988" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Nodular lymphocyte predominant Hodgkin lymphoma. An immunophenotypic reappraisal based on a single-institution experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9256483" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9250848" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Clonality in nodular lymphocyte-predominant Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16699312" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : IgD positive L&amp;H cells identify a unique subset of nodular lymphocyte predominant Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18794340" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24244368" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma--endpoints of a spectrum of one disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393409" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16049307" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Molecular cytogenetic analyses of immunoglobulin loci in nodular lymphocyte predominant Hodgkin's lymphoma reveal a recurrent IGH-BCL6 juxtaposition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26658840" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30213827" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : JUNB, DUSP2, SGK1, SOCS1 and CREBBP are frequently mutated in T-cell/histiocyte-rich large B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24525501" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : EBV may be expressed in the LP cells of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in both children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20048177" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26837698" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20029973" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25644177" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19797726" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
